These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32133883)

  • 1. Pneumococcal vaccination in lung transplant patients.
    Holzer L; Hoffman T; Van Kessel DA; Rijkers GT
    Expert Rev Vaccines; 2020 Mar; 19(3):227-234. PubMed ID: 32133883
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation.
    Langedijk AC; van Aalst M; Meek B; van Leeuwen EMM; Zeerleder S; Meijer E; Hazenberg MD; Grobusch MP; Goorhuis A
    Vaccine; 2019 Jan; 37(3):510-515. PubMed ID: 30502071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pneumococcal vaccines: what are the advantages for the elderly?
    Vila-Córcoles A
    Drugs Aging; 2007; 24(10):791-800. PubMed ID: 17896829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evidence for use of pneumococcal conjugate over polysaccharide in children.
    Borrow R
    Hum Vaccin Immunother; 2013 Jun; 9(6):1385-6. PubMed ID: 23732895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal immunization in immunocompromised hosts: where do we stand?
    Cordonnier C; Averbuch D; Maury S; Engelhard D
    Expert Rev Vaccines; 2014 Jan; 13(1):59-74. PubMed ID: 24308578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
    Papadatou I; Spoulou V
    Clin Vaccine Immunol; 2016 May; 23(5):388-395. PubMed ID: 27009210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Follow-up of Humoral Immune Status in Adult Lung Transplant Recipients.
    van Kessel DA; Hoffman TW; Kwakkel-van Erp JM; Oudijk ED; Zanen P; Rijkers GT; Grutters JC
    Transplantation; 2017 Oct; 101(10):2477-2483. PubMed ID: 28198768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
    Mitchell R; Trück J; Pollard AJ
    Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants.
    Nurkka A; Joensuu J; Henckaerts I; Peeters P; Poolman J; Kilpi T; Käyhty H
    Pediatr Infect Dis J; 2004 Nov; 23(11):1008-14. PubMed ID: 15545855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
    Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
    JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune status assessment in adult lung transplant candidates.
    van Kessel DA; Hoffman TW; van Velzen-Blad H; van de Graaf EA; Grutters JC; Rijkers GT
    Transpl Immunol; 2017 Feb; 40():31-34. PubMed ID: 27867073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.